Clinical Trials Browser

Phase 3 × Recruiting × Myeloid × Clear all

Polycythemia Vera

NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Phase 3 Recruiting

665 enrolled

Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT06499285 2026-05-13

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Phase 3 Recruiting

225 enrolled

Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes

NCT04116502 2026-04-28

MITHRIDATE

Phase 3 Recruiting

586 enrolled

Myeloid

Polycythemia Vera

NCT06351631 2026-04-02

MK-3543-017

Phase 3 Recruiting

400 enrolled

Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT06093672 2026-03-25

GIV-IN-PV

Phase 3 Recruiting

220 enrolled

Myeloid

Polycythemia Vera

NCT05198960 2026-03-20

AVAJAK

Phase 3 Recruiting

1,308 enrolled

Classical hematologyMyeloid

Hemorrhage, Polycythemia Vera, Thrombocythemia, Essential, Venous Thromboembolism, Primary Myelofibrosis

NCT06468033 2025-08-13

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Phase 3 Recruiting

150 enrolled

Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT06423911 2025-06-03

POLARIS-2

Phase 3 Recruiting

285 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT05991908 2025-02-18

Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies

Phase 3 Recruiting

222 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06740916 2024-12-27

Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance

Phase 3 Recruiting

240 enrolled

Myeloid

Myeloproliferative Disorders

NCT04655092 2024-11-08

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Phase 3 Recruiting

67 enrolled

Myeloid

Myeloproliferative Disorders, Polycythemia Vera

NCT03459534 2024-10-28

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Phase 3 Recruiting

173 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Clinical Trials

INTREPID

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

MITHRIDATE

MK-3543-017

GIV-IN-PV

AVAJAK

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

POLARIS-2

Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies

Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs